This review in The Lancet Infectious Diseases sets out a problem every hospital prescriber meets. Daptomycin has no FDA or EMA licence for enterococcal infection and no randomised trials behind it, yet it has become a mainstay for serious enterococcal bacteraemia and endocarditis. Susceptibility guidance conflicts: CLSI calls Enterococcus faecium susceptible dose-dependent at MIC 4 mg/L or less with 8–12 mg/kg daily, and E faecalis susceptible at 2 mg/L or less with 6 mg/kg, while EUCAST sets no clinical breakpoint at all.
The authors argue that this mismatch causes harm through underdosing. Observational data associate 10–12 mg/kg daily with lower mortality in vancomycin-resistant E faecium. Even then, the drug often fails to reach its pharmacodynamic target, because that depends on the isolate's MIC, which routine methods measure unreliably. Creatine kinase rises modestly with dose in the largest registry, with a clearer signal for marked rises at the top doses.
They propose at least 8 mg/kg daily for E faecium, 10–12 mg/kg in vancomycin-resistant disease, dose choice informed by the MIC, a β-lactam partner in endocarditis, and weekly creatine kinase. This is expert synthesis of observational evidence, not trial data, and it does not change any licence. But where 6 mg/kg is still the default for enterococcal bacteraemia, it is a strong argument to discuss higher dosing with microbiology.
- For Enterococcus faecium bacteraemia, consider daptomycin at 8 mg/kg daily or more, rather than 6 mg/kg.
- For vancomycin-resistant E faecium, the review proposes 10–12 mg/kg daily.
- Ask the laboratory for the daptomycin MIC and how it was measured; borderline values deserve the higher dose.
- In enterococcal endocarditis, discuss adding a β-lactam to daptomycin with infectious diseases.
- Check creatine kinase weekly, more closely at the highest doses.
Why it matters
A dose that looks standard on the drug chart may be too low for the organism being treated.
Don't overread it
The dosing framework rests on observational data and expert opinion; no randomised trial supports it and no licence covers it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free